Insomnia · Prescription digital therapeutic

SleepQ®

Prescription software for insomnia treatment

Sleep records guide a personalized sleep schedule and six weeks of cognitive behavioral therapy.

Korea’s first integrated reviewInsurance listingCE marked

MFDS authorization 23-511 · Used with a prescription

SleepQ product screen
Product screenSix weeks of CBT-I
Actual German-language SleepQ product screen
SleepQ® · Europe

SleepQ®, from Korea to Europe

With European CE marking and a clinical study with Charité Berlin, SleepQ® is preparing to enter the German market.

European CE marking
EU Medical Device Regulation (MDR) · 2025
Clinical study with Charité Berlin
WELT-REST · Patient follow-up complete; results analysis underway
Preparing for German statutory coverage
Preparing for listing as a digital health application (DiGA)
How SleepQ® works

How SleepQ® supports treatment

Daily sleep records guide your sleep schedule and treatment program.

01 · Sleep diary

Record last night’s sleep each morning

Record bedtimes, wake times and sleep quality to understand your sleep pattern.

02 · Personalized sleep schedule

A sleep schedule based on your records

From week 2, recommended sleep times are guided by your records and updated weekly.

03 · Daily treatment program

Work on habits and thoughts that affect sleep

Learn through Sleep Exploration, find answers in Sleep Talk and practice relaxation exercises.

Screens from the user guide; the software may differ by software version.

Six-week treatment

A program guided by your sleep records

  1. Week 1

    Start your sleep diary

    Complete the initial questionnaire and record your sleep each day.

  2. Weeks 2–6

    Personalized goals and treatment

    Your recommended sleep schedule is updated weekly as you follow the treatment program.

  3. After six weeks

    Review your progress

    Review your outcomes with your clinician using the final questionnaire and sleep records.

SleepQ® · Clinical evidence

Greater improvement in sleep efficiency

Peer-reviewed
Participants
Adults with insomnia
Comparator
Sham software
Assessment
Six weeks of treatment; week-seven assessment

Improvement in sleep efficiency from baseline

SleepQ®15.14pp
Sham software control6.86pp

Sleep efficiency is the proportion of time in bed spent asleep. Bars show adjusted changes from baseline in percentage points (pp).

Between-group difference+8.28pp

SleepQ® improved sleep efficiency by 8.28 percentage points more than the sham software control.

A percentage point (pp) is the unit used for the difference between two percentages.

p = 0.0418
Study design and interpretation
Design
Double-blind, sham-controlled randomized trial / Severance Hospital
Population
68 randomized; efficacy analysis of 54 (SleepQ® 28, control 26)
Assessment
After six weeks of treatment; seven weeks including assessment
Statistics
Difference 8.28 percentage points; 95% CI 0.32–16.24; effect size d = 0.68
Safety
Eight mild adverse events were reported. No device-related or serious adverse events were reported.
RWE · Routine clinical care

Improvement in insomnia symptoms
in routine clinical care

An RWE analysis of patients prescribed SleepQ® estimated an average 6.59-point reduction in the Insomnia Severity Index (ISI) from before to after treatment.

37

Participating hospitals

−6.59 points

Average ISI change from before treatment

What this measure means

The ISI is a questionnaire that measures insomnia symptom severity. Lower scores indicate less severe symptoms, so a lower average score reflects improvement.

SleepQ® milestones

SleepQ®: Korea’s first integrated innovative-device review

MFDS authorization

23-511 · Innovative device No. 25

First integrated review

A pathway from authorization to clinical use

Prescribing and evaluation fees

TU001 prescribing · TU002 evaluation · TX010 use fee (non-covered)

Nationwide prescribing

Full-scale commercial rollout to hospitals

The SleepQ® usage fee is a recognized non-covered item, distinct from National Health Insurance benefit coverage. Confirm charges with the provider and private coverage with your insurer.

HIRA guidance ↗
Authorization

MFDS 23-511, April 2023 · Innovative device No. 25 · CE(MDR), 2025

Platform

DrugOS™ · CBT-I

Need help getting started?

Find registration steps and daily program instructions in the patient guide.